ImmuCell (ICCC)
(Delayed Data from NSDQ)
$6.00 USD
-0.37 (-5.81%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $6.09 +0.09 (1.50%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ICCC 6.00 -0.37(-5.81%)
Will ICCC be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ICCC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ICCC
ImmuCell Upgraded to Outperform on Sales Surge & FDA Upside
The Zacks Analyst Blog Highlights Alphabet, Oracle, Shell, Fossil and ImmuCell
ICCC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Top Research Reports for Alphabet, Oracle & Shell
ImmuCell Reports Y/Y Q1 Earnings Growth on Record Sales & Margin Gains
The Zacks Analyst Blog Netflix, SAP SE, Shell, Preformed Line Products and ImmuCell
Other News for ICCC
ICCC Plans Capacity Upgrade to Meet North American Market Demand | ICCC Stock News
Immucell reports preliminary unaudited Q1 revenue $6.4M vs. $5.5M last year
ImmuCell (ICCC) Stock Trading Resumes | ICCC Stock News
ImmuCell (ICCC) Trading Halted Due to Volatility | ICCC Stock News
ImmuCell trading resumes